Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial ResultsMarch 13, 2018
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)February 8, 2018
Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018January 30, 2018
Press Release History
Website Developed by Alan Leff Associates, Inc.